Ratings aTyr Pharma, Inc.

Equities

LIFE

US0021202025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2 ^USD	+3.63%		+18.34%	+41.84%

May. 14	ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis	CI
May. 02	ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ATYR PHARMA, INC.	+41.84%	138M	-
MODERNA, INC.	+33.63%	50.93B	B-
IQVIA HOLDINGS INC.	-0.09%	42.12B	B
LONZA GROUP AG	+49.62%	42.05B	A
CELLTRION, INC.	-4.96%	29.18B	C
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B	B
BIO-TECHNE CORPORATION	+8.61%	13.21B	B+
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B	B+
MEDPACE HOLDINGS, INC.	+28.31%	12.16B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes